Echo Therapeutics is a medical device and specialty pharmaceutical company based out of Franklin, Massachusetts. The company is focused on developing a trans-dermal continuous glucose monitoring (tCGM) system and developing reformulations of a variety of FDA-approved specialty pharmaceutical products.
Echo is applying its patented AzoneTS™ trans-dermal drug formulation technology to create a suite of topical reformulations on FDA-approved products that are on the market today. The company plans to create the reformulations in accordance with the FDA’s Section 505(b)(2) guidelines. Echo intends to capitalize on its long-term relationship with Cato Research, a global contract research and development organization (CRO), and work in tandem with Cato to develop its suite of improved topical products.
Echo’s lead drug candidate, Durhalieve™, is an AzoneTS topical reformulation of triamcinolone acetonide. The company has submitted a new Drug Application (NDA) with the FDA classifying Durhalieve™ as a new, proprietary treatment for corticosteroid responsive dermatoses. By late-2008, Echo hopes to submit an Investigational New Drug (IND) application with the FDA that will allow Phase 2 clinical development of Durhalieve for treatment of keloid scarring and hypertrophic scarring.
The company is currently developing the next-generation glucose monitoring system for home or hospital use for diabetic patients. Echo’s Symphony™ System is slated to change the invasive and periodic glucose testing diabetic patients currently perform. Symphony™ combines Echo’s patented feedback mechanism for optimal skin permeation control with a non-invasive trans-dermal biosensor to provide continuous data on a patient’s glucose level. With the increasing number of individuals being diagnosed with Type-2 diabetes each year, the Symphony™ system will potentially improve patient compliance with better glucose control throughout the day, providing an improved quality of life for patients.
Let us hear your thoughts: Echo Therapeutics, Inc. Message Board